Advancements and Opportunities in the Intravenous Immunoglobulin (IVIG) Market: A Comprehensive Analysis from 2022 to 2031

The global Intravenous Immunoglobulin (IVIG) market encompasses a range of indications including Chronic Inflammatory Demyelinating Polyneuropathy, Primary Humoral Immunodeficiency, Idiopathic Thrombocytopenic Purpura, Guillain-Barre Syndrome, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Disease, Hypogammaglobulinemia, Chronic Lymphocytic Leukemia, among others. The market analysis spans from 2022 to 2031, focusing on industry trends, growth factors, and forecasts.

Request to View Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1930

Market Overview

The IVIG market was valued at US$ 11.2 billion in 2021 and is projected to grow at a CAGR of 7.3% from 2022 to 2031, reaching a value of US$ 20.5 billion by 2031. Key drivers of market growth include the increasing prevalence of autoimmune diseases, technological advancements in production methods, rising geriatric population, and expanding patient pool necessitating efficient treatment options.

Rise in R&D Activities

Research and development activities in the IVIG sector are expected to drive market growth. Recent clinical trials exploring IVIG's efficacy in treating conditions such as COVID-19 demonstrate the potential of this therapy. Government initiatives supporting intravenous delivery methods further contribute to market expansion.

Incidence of Primary Immunodeficiency Diseases

The surge in primary immunodeficiency diseases, such as hypogammaglobinemia, contributes significantly to market growth. The increase in chronic immune defects globally emphasizes the importance of IVIG therapy in managing these conditions.

Preference for Hospital Treatment

Hospitals dominate the end-user segment of the IVIG market due to the preference for hospital-based treatments and the improved quality of life offered by IVIG infusions at home. This trend is expected to persist, driving market demand.

Impact of the COVID-19 Pandemic

The COVID-19 pandemic has accelerated market growth, with IVIG emerging as a potential treatment for severe cases. The high susceptibility of immune-deficient individuals to COVID-19 underscores the importance of IVIG therapy in managing the pandemic.

Analysis of Key Players

The global IVIG market is characterized by the presence of numerous players, both international and regional. Key players include Baxalta Incorporated, Biotest AG, China Biologic Products, Inc., CSL Behring LLC, Grifols S.A., Kedrion S.p.A., LFB Biomedicaments S.A., Octapharma AG, and Sanquin Plasma Products B.V. Market growth is further fueled by the growing burden of target diseases and increased research and development activities, particularly in North America.

Download PDF Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1930

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.